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Abstract 
Review on KLK6, with data on DNA, protein, and 
where the gene is involved. 
Keywords 
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Identity 
Other names: Bss, Klk7, PRSS18, PRSS9, SP5, 
hK6 
HGNC (Hugo): KLK6 
Location: 19q13.41 
Figure 1. Graphic illustration of the KLK6 gene. Boxes denote exons and connecting lines represent introns. The coding 
sequences are colored in green, while 5' and 3' untranslated regions (UTRs) are shown in white. The numbers inside or outside 
boxes indicate lengths (nt) of exons and introns, respectively, while the numbers in parentheses indicate lengths (aa) of protein 
isoforms. Arrows mark the position of the start codons (ATG) and asterisks (*) mark the position of the stop codon (TGA). The 
figure is drawn in scale, except for the introns containing the (//) symbol. For each transcript, the splice variant number, the 
GenBank accession number and the protein isoform number are shown next to each transcript (Adamopoulos et al., 2017) 
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Figure 2. Alignment of 4 out of the 8 isoforms of the KLK6 protein. The signal peptide, glycosylation site, catalytic triad, and 
disulfide bonds are marked on the main isoform (isoform 1). The other four isoforms that are not presented align only partially 




The KLK6 gene is located on 19q chromosome, has 
a total length of 11.043 nt, and consists of 7 exons 
and 6 introns. 
Transcription 
KLK6 pre-mRNA is subjected to alternative 
splicing. Six (6) variants had previously been 
detected, while another 6 transcripts have recently 
been identified by our research group (Adamopoulos 
et al., 2017). Furthermore, one more variant is 
predicted, based on similarity to 50 ESTs. Each of 
them has a different exon and intron structure. The 
main variant (variant A) consists of 7 exons and 6 
introns. The first 2 introns do not include coding 
regions and compose the 5UTR. The other 11 
variants range from 3 to 7 exons and 2 to 6 introns, 
while some of them bare similarity to each other. The 
structures of all variants are clearly illustrated in 
Figure 1. 
Pseudogene 
Not detected so far. 
Protein 
Description 
Eight different isoforms of KLK6 protein have been 
detected, consisting of 244, 137, 120, 149, 42, 138 
277, and 182 amino acid (aa) residues, respectively. 
The KLK6 gene encodes a single-chain pre-
proenzyme, which is enzymatically inactive. After 
the removal of the signal peptide (16 aa) from the 
pre-proenzyme, an inactive proKLK is formed and 
secreted to the extracellular space, where it is finally 
transformed into the active KLK through further 
cleavage (Bayani  Diamandis, 2011). 
Expression 
KLK6 is highly expressed in cerebral cortex, tonsil, 
spleen, esophagus, kidney, fallopian tube and breast. 
Localisation 
KLK6 is mainly localized to nucleoplasm, nuclear 
membrane and cytokinetic bridge. 
Function 
KLK6 is a serine protease, involved in proteolytic 
cascades. KLK6 has been suggested to be 
autoactivated or activate other proKLKs. When 
activated, serine proteases are usually regulated by 
binding to serpins (serine protease inhibitors), which 
prompts to their inactivation. A preference for Arg 
over Lys in the substrate P1 position and for Ser or 
Pro in the P2 position is detected in KLK6 substrate. 
Three amino acid residues (positions: 62, 106, and 
197) constitute the catalytic triad in the main protein 
isoform (isoform 1, 244 aa) that is responsible for 
serine protease activity. An Asp residue at position 
191 suggests a trypsin-like activity, while 
chymotrypsin activity is suggested by a loop similar 
to chymotrypsin 3D-structure. However, 
chymotrypsin activity is rejected by recent studies. 
KLK6 is activated against amyloid precursor 
protein, which is associated with Alzheimer's 
disease, myelin basic protein, and casein. 
Furthermore, it participates in the degradation of 
extracellular matrix (ECM) proteins, namely 
fibronectin, laminin, vitronectin, laminin and 
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collagen. It is involved in alpha-synuclein 
degradation and in the inhibition of its 
polymerization. This fact demonstrates the potential 
role of KLK6 in Parkinson's disease. Furthermore, 
KLK6 plays a role in cancer invasion and metastasis 
(Bayani  Diamandis, 2011). 
Mutations 




KLK6 is overexpressed in gastric cancer tissues. 
Elevated expression of KLK6 is linked to lymphatic 
invasion and unfavorable patient prognosis and may 
be associated with pericellular proteolysis. KLK6 
gene silencing successfully reduces tumor cell 
proliferation and invasion (Nagahara et al., 2005). 
Non-Small Cell Lung Cancer (NSCLC) 
Prognosis 
KLK6 expression is elevated in NSCLC tumor tissue 
and is involved in NSCLC development and 
progression. High KLK6 concentration is related to 
poor survival rates, and patients with KLK6 
overexpression are characterized by unfavorable 
prognosis (Heuzé-Vourc'h et al., 2009). 
Ovarian cancer 
Prognosis 
KLK6 protein expression is elevated in ovarian 
cancer, in both tumor and surrounding stromal cells. 
KLK6 is more often overexpressed in serous ovarian 
carcinoma than in endometrioid and mucinous 
carcinomas. It has been found to be transcriptionally 
regulated by hormones; KLK6 represents a 
downstream molecule by which a hormone-related 
neoplasm initiates and invades through degradation 
of the extracellular matrix and interaction with 
angiogenic factors. Gene amplification is suggested 
as a possible mechanism of high KLK6 presence in 
ovarian tumors. KLK6 derived by stromal cells is 
associated with the aggressive ovarian neoplasm. 
Unique patterns of N-glycosylation of KLK6 have 
been found; parts of sialic acid on KLK6 are 
abundant, almost exclusively, in ovarian cancer 
cells. KLK6 has been suggested as a prognostic 
biomarker for ovarian cancer, and is applicable in 
every stage, including the early one. Furthermore, it 
can be used in combination with MUC16 (CA-125), 
KLK10 and KLK13, in a multivariate model with 
increased prognostic power (Ni et al., 2004; White et 
al., 2009; Kuzmanov et al., 2009; Seiz et al., 2012). 
Breast Cancer 
Prognosis 
In the majority of metastatic breast cancers, KLK6 is 
deregulated. The mechanism behind this 
deregulation is genomic DNA methylation. 
Specifically, KLK6 has a tumor-protective activity 
against breast cancer, which derives from KLK6 
loss-of-function, due to hypermethylation of CpG 
dinucleotides. On the other hand, overexpression of 
KLK6 was related to demethylation of the CpG 
dinucleotides. Modulation of KLK6 expression 




KLK6 has proved to induce early skin cancer 
through the development of skin inflammation. 
Deficiency of KLK6 is linked to the suppression of 
chemically-induced skin cancer. KLK6 suspends 
CDH1 (E-cadherin) expression and leads to 
accumulation of CTNNB1 (beta-catenin). Moreover, 
it is involved in progression of skin cancer and 
migration of cancer cells in squamous skin tumors 
(Klucky et al., 2007). A role of KLK6 in neoplastic 
transformation and malignant progression in 
melanoma has been demonstrated, as well (Krenzer 
et al., 2011). 
Colorectal cancer (CRC) 
Prognosis 
KLK6 expression in CRC has been reported to be 
elevated when a mutation in KRAS oncogene, which 
is strongly related to CRC, is abundant. Its 
expression is also increased through caveolin 1 ( 
CAV1) activity. CAV1 is overexpressed in CRC and 
acts on the PI3K/AKT pathway, by decreasing the 
activity of negative regulatory phosphatases, such as 
PPA1 and PTPA (PP2A). This leads to KLK6 gene 
overexpression. KLK6 has proved to participate in 
invasion and KRAS-dependent migration 
(Henkhaus et al., 2008a). This occurs due to its 
serine protease-ability to degrade EMC components 
(collagen, laminin, fibronectin). KLK6 is also 
involved in proteolytic cascades leading to the 
activation of certain enzymes which are involved in 
pericellular proteolysis and subsequently, to tumor 
invasion. Proteolysis of ECM components leads to 
disruption of their interaction with cells and is 
associated with tumor cell growth and malignant 
transformation. KLK6 serves as a possible indicator 
in CRC. This is enhanced by the fact that a combined 
analysis of KLK6 and carcinoembryonic antigen 
(CEA) in lymph nodes is able to identify CRC 
patients with high risk of relapse (Henkhaus et al., 
2008b; Ohlsson et al., 2012; Petraki et al., 2012). 
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